Serologic TB Test Using Membrane Vesicle Antibody Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current tuberculosis diagnosis methods, especially in resource-limited settings, are hindered by the need for laboratory infrastructure, long turn-around times, and limited sensitivity and specificity, necessitating a simple, rapid, and cost-effective test that can detect active TB using easily accessible samples independent of the disease site.
Innovation Solution
A method involving contacting a sample with agents capable of binding IgG, IgA, and/or IgM antibodies directed to specific proteins on Mycobacterium tuberculosis or Bacillus Calmette-Guérin membrane vesicles, allowing for the detection of active TB through a kit comprising agents targeting distinct proteins with different molecular masses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If culture methods are used for TB diagnosis, then diagnostic accuracy is improved, but turn-around-time increases to weeks or months
Solution Approach 1:
The patent extracts and detects specific biomarkers (urine antigens LAM and PDIM, serum antibodies) from patient samples using immunological assays. This extraction of key diagnostic indicators enables rapid detection without requiring full culture procedures, achieving both speed and accuracy by focusing only on the most informative markers.
Solution Approach 2:
The patent replaces the mechanical culture system (requiring incubation and observation of bacterial growth) with immunological detection systems (ELISA, lateral flow assays) that detect biomarkers directly. This substitution eliminates the need for lengthy culture incubation while maintaining diagnostic accuracy through specific antibody-antigen recognition.
2Productivity
If molecular methods like GeneXpert are used, then diagnostic speed and accuracy are improved, but cost and technological investment requirements increase
Solution Approach 1:
The patent employs disposable immunological test formats such as lateral flow assays and ELISA kits that use pre-coated antibodies and antigens. These single-use test strips and plates eliminate the need for expensive, complex molecular instrumentation while providing rapid results at low cost, making them suitable for resource-limited settings.
Solution Approach 2:
The patent uses immunological assays that detect biomarker patterns (multiple antigens and antibodies) as a surrogate for direct bacterial detection. This copying approach through biomarker detection provides equivalent diagnostic information to molecular methods but with simpler, cheaper technology that does not require sophisticated equipment.
3Speed
If microscopy is used for rapid TB diagnosis, then speed is improved, but sensitivity is limited to around 50%
Solution Approach 1:
The patent introduces immunological assays as an intermediary detection method between microscopy and culture. These assays use antibodies and antigens as mediators to detect TB biomarkers in urine and serum, providing higher sensitivity than microscopy by detecting molecular markers rather than requiring visible bacterial forms, while maintaining rapid turnaround time.
Solution Approach 2:
The patent changes the detection parameter from visual observation of acid-fast bacilli (microscopy) to quantitative detection of biomarker concentrations (immunological assays). This parameter change from morphological detection to molecular detection increases sensitivity while maintaining speed, as the assays can detect trace amounts of antigens and antibodies that microscopy cannot visualize.
4Ease of operation
If serodiagnostic tests are used, then simplicity and cost-effectiveness are improved, but sensitivity and specificity are insufficient
Solution Approach 1:
The patent segments the diagnostic approach by detecting multiple distinct biomarkers (urine LAM antigen, urine PDIM antigen, serum IgG antibodies, serum IgA antibodies) rather than relying on a single test. This multi-marker panel strategy increases both sensitivity and specificity while maintaining the simplicity of immunological assays, as each marker provides independent diagnostic information.
Solution Approach 2:
The patent creates a composite diagnostic strategy combining multiple immunological assays (urine antigen detection, serum antibody detection) targeting different biomarkers. This composite approach integrates multiple detection systems to achieve high sensitivity and specificity while preserving the operational simplicity of point-of-care immunological tests.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables rapid and accurate detection of active TB, distinguishing it from latent infection, and can be adapted for minimal laboratory infrastructure, providing a sensitive and specific diagnostic tool.
Implementation Method 1
contacting a sample with agents capable of binding IgG, IgA, and/or IgM antibodies directed to specific proteins on Mycobacterium tuberculosis or Bacillus Calmette-Guérin membrane vesicles
Data Source
AI summary
The present invention relates to methods and kits for detecting active tuberculosis infection in a subject using serological techniques and a first agent capable of binding an IgG, IgA and/or IgM directed to the first protein present in or on a Mycobacterium tuberculosis membrane vesicle or a Bacillus Calmette-Guerin (BCG) membrane vesicle. Also provided are methods of treating a subject with an active tuberculosis disease.